Skip to main content

Innovations and Research

As one of five thalassemia centers in the United States designated by the National Institutes of Health, the Children's Hospital Boston thalassemia program provides patients with access to experts in the field and the most cutting-edge clinical trials available in the world. One promising recent study, now awaiting approval by the FDA, tested the effectiveness of a new oral iron chelator, deferisirox.
Researchers from Children's Hospital Boston have been at the forefront of thalassemia research and treatment for decades. Important advances in the field that were made here include:

• Recognition of the important role of hypertransfusion
by Dr. David Nathan, Senior Associate in Hematology, in the 1960s.
• Demonstration of effective iron chelation by subcutaneous pump deferoxamine (Desferal ®)
by Dr. Richard Proper and David Nathan in the 1970s.
• Elucidation of the molecular biology of thalassemia syndromes
by Drs. Nathan, YW Kan, Stuart Orkin and others.
Labels:

Comments

Post a Comment

Popular posts from this blog

Thalassemia Minor: Understanding the Silent Carrier

Introduction: Thalassemia is a genetic blood disorder characterized by abnormal hemoglobin production, leading to anemia. Thalassemia minor, also known as thalassemia trait or carrier state, is the mildest form of thalassemia. Individuals with thalassemia minor typically have one normal hemoglobin gene and one mutated hemoglobin gene. Although it is considered a mild condition, understanding thalassemia minor is crucial due to its implications for genetic counseling and potential complications during pregnancy. Genetic Basis and Inheritance: Thalassemia minor is inherited in an autosomal recessive manner, meaning that both parents must carry the gene mutation for their child to have thalassemia minor. The mutated genes affect the production of either the alpha or beta globin chains that make up hemoglobin, the protein responsible for carrying oxygen in the blood. The severity of thalassemia is influenced by the specific gene mutation and the extent to which the normal gene is affected....
Post a Comment
Read more

Living With Thalassemias

Survival and quality of life are now much better for people who have moderate or severe forms of thalassemia. This is because: * More people are able to get blood transfusions now. * Blood screening has reduced the number of infections from blood transfusions. Also, treatments for other kinds of infections have improved. * New iron chelation treatments are available that are easier for some people to take. * Some people have been cured through blood and marrow stem cell transplants. Living with thalassemia can be challenging, but several approaches can help you cope. Follow Your Treatment Plan It's important to follow the treatment plan your doctor gives you. Get blood transfusions as he or she recommends. Take your iron chelation medicine. This is important because the leading cause of death among people with thalassemias is heart disease caused by iron overload. Iron buildup can damage your heart, liver, and other organs. Although the iron chelation treatment can ...
Post a Comment
Read more

Alpha Thalassemias

Four genes (two from each parent) are needed to make enough alpha globin protein chains. If one or more of the genes is missing, you will have alpha thalassemia trait or disease. This means that you don't make enough alpha globin protein. * If you have only one missing gene, you're a silent carrier and won't have any signs of illness. * If you have two missing genes, you have alpha thalassemia trait (also called alpha thalassemia minor). You may have mild anemia. * If you have three missing genes, you likely will have hemoglobin H disease (which a blood test can detect). This form of thalassemia causes moderate to severe anemia. Very rarely, a baby will have all four genes missing. This condition is called alpha thalassemia major or hydrops fetalis. Babies with hydrops fetalis usually die before or shortly after birth.
Post a Comment
Read more